Overview

Trial of Sunitinib for Refractory Malignant Ascites

Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.
Phase:
Phase 2
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Treatments:
Sunitinib